Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia

Gudiol C., Royo-Cebrecos C., Abdala E., AKOVA M., Alvarez R., Maestro-de la Calle G., ...More

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.61, no.8, 2017 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Article
  • Volume: 61 Issue: 8
  • Publication Date: 2017
  • Doi Number: 10.1128/aac.00164-17
  • Journal Indexes: Science Citation Index Expanded, Scopus


beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.